NCT06036602View on ClinicalTrials.gov

Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Ebola Sudan Virus Disease
Interventions
BIOLOGICAL

cAD3-Sudan Ebolavirus Vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.

OTHER

Placebo

0.9% NaCl solution for injection.

Trial Locations (2)

Unknown

KEMRI/Centre for Respiratory Disease Research Siaya Clinical Research Annex, Siaya

Makerere University-Walter Reed Project, Kampala

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Albert B. Sabin Vaccine Institute

OTHER

NCT06036602 - Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter